Lakefront Biotherapeutics (GLPGF) Net Cash Flow (2015 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Net Cash Flow for 12 consecutive years, with -$25.5 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Net Cash Flow fell 153.68% year-over-year to -$25.5 million in Q1 2026; TTM through Mar 2026 was $152.1 million, a 18.33% decrease from a year earlier, with the FY2025 full-year figure at $31.7 million, up 128.09% from the prior year.
• Net Cash Flow was -$25.5 million for Q1 2026 at Lakefront Biotherapeutics, down from $28.8 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $83.9 million in Q2 2025 and troughed at -$1.8 billion in Q4 2022.
• A 5-year average of -$264.3 million and a median of $7.9 million in 2024 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow plunged 344.3% in 2022 and surged 265.08% in 2025, its largest moves.
• Over 5 years, Net Cash Flow stood at -$1.8 billion in 2022, then jumped by 79.81% to -$360.0 million in 2023, then surged by 102.19% to $7.9 million in 2024, then surged by 265.08% to $28.8 million in 2025, then tumbled by 188.41% to -$25.5 million in 2026.
• The last three Net Cash Flow figures came in at -$25.5 million (Q1 2026), $28.8 million (Q4 2025), and $64.9 million (Q3 2025), per Business Quant data.